<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Primary bedwetting without daytime symptoms | Management | Bedwetting (enuresis) | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of children with primary bedwetting without daytime symptoms in primary care."/><meta data-react-helmet="true" property="og:description" content="Covers the management of children with primary bedwetting without daytime symptoms in primary care."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/bedwetting-enuresis/management/primary-bedwetting-without-daytime-symptoms/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Primary bedwetting without daytime symptoms | Management | Bedwetting (enuresis) | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/bedwetting-enuresis/management/primary-bedwetting-without-daytime-symptoms/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Bedwetting (enuresis)</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Primary bedwetting without daytime symptoms</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/bedwetting-enuresis/","name":"Bedwetting (enuresis)"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/bedwetting-enuresis/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Primary bedwetting without daytime symptoms"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Bedwetting (enuresis): </span><span>Scenario: Primary bedwetting without daytime symptoms</span></h1><p class="page-header__lead"><span>Last revised in March 2020</span></p></div><p class="visually-hidden">Covers the management of children with primary bedwetting without daytime symptoms in primary care.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Bedwetting (enuresis) chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Primary bedwetting without daytime symptoms"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Primary bedwetting without daytime symptoms</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Primary bedwetting with daytime symptoms"><a aria-current="false" href="../primary-bedwetting-with-daytime-symptoms/index.html"><span class="stacked-nav__content-wrapper">Scenario: Primary bedwetting with daytime symptoms</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Secondary bedwetting"><a aria-current="false" href="../secondary-bedwetting/index.html"><span class="stacked-nav__content-wrapper">Scenario: Secondary bedwetting</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#management-children-younger-than-5-years">Management - children younger than 5 years</a><ol aria-label="Sections within Management - children younger than 5 years" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-6ac">Basis for recommendation</a></li></ol></li><li><a href="index.html#management-children-5-years-older">Management - children 5 years and older</a><ol aria-label="Sections within Management - children 5 years and older" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ded">Basis for recommendation</a></li></ol></li><li><a href="index.html#enuresis-alarms">Enuresis alarms</a><ol aria-label="Sections within Enuresis alarms" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#information-advice">Information and advice</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-117">Basis for recommendation</a></li></ol></li><li><a href="index.html#desmopressin">Desmopressin</a><ol aria-label="Sections within Desmopressin" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#information-advice">Information and advice</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-d97">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-recurrence">Managing recurrence</a><ol aria-label="Sections within Managing recurrence" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1ba">Basis for recommendation</a></li></ol></li><li><a href="index.html#sources-of-information-support">Sources of information and support</a></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="primary-bedwetting-without-daytime-symptoms" class="ChapterBody-module--wrapper--2HCfk "><h2 id="primary-bedwetting-without-daytime-symptoms" class="visually-hidden">Scenario: Primary bedwetting without daytime symptoms</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dab1d949-517d-4658-9f36-6d50a04f077a --><!-- begin field cb95667e-9e92-4c5a-88a0-acbc015925d1 --><p>From age 24 months to 19 years.</p><!-- end field cb95667e-9e92-4c5a-88a0-acbc015925d1 --><!-- end item dab1d949-517d-4658-9f36-6d50a04f077a --></div><section aria-labelledby="management-children-younger-than-5-years" class="ChapterBody-module--wrapper--2HCfk "><h3 id="management-children-younger-than-5-years">How should I managebedwetting without daytime symptoms in children younger than 5 years of age?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ef1efed1-57c7-47de-b1de-da92c60c55c9 --><!-- begin field 280ece48-708a-421c-b3b4-e705d174a34b --><ul><li><strong>Explain that bedwetting is not the child's fault.</strong><ul><li>It occurs because the volume of urine produced at night exceeds the capacity of the bladder to hold it, and the sensation of a full bladder does not wake the child.</li></ul></li><li><strong>Reassure the parents or carers that many children younger than 5years of age wet the bed, and this usually resolves without treatment.</strong><ul><li>Bedwetting usually resolves as children get older because they develop an increased bladder capacity,<em>and/or</em>produce less urine at night,<em>and/or</em>learn to wake to the sensation of a full bladder.</li></ul></li><li><strong>Giveadvice on:</strong><ul><li><strong>Diet andfluid intake.</strong>Advise that the child should:<ul><li>Eat ahealthy diet; they shouldnot restrict their diet as a form of treatment for bedwetting.</li><li>Haveadequatedaily fluid intake.</li><li>Avoid drinking caffeine-based drinks (such as colas, coffee, and tea) before sleep.</li></ul></li><li><strong>Toileting patterns.</strong>Advise that:<ul><li>The child shouldbe encouraged to empty their bladder regularly during the day and before sleep (between 47 times in total).</li><li>A waterproof mattress and duvet cover, absorbent quilted sheets, and bed pads can be used.</li><li>There should be easy access to a toilet and/or pottyat night.</li><li>If the child has been toilet trained by day for longer than 6months, they should consider a trial of at least 2nights in a row without nappies or pull ups (appropriate waterproof mattress protection will be required).</li></ul></li><li><strong>Lifting and waking.</strong>Advise that:<ul><li>Lifting or waking the child during the night (at regular times or randomly) does not promote long-term dryness. However, if the child wakes at night, they should be taken to the toilet.</li><li>Waking of children should be used only as a practical measure in the short-term management of bedwetting.</li></ul></li><li><strong>Positive reward systems</strong><strong>.</strong>Advise that:<ul><li>Positive reward systems may be offered to children who have some dry nights.They should be adapted to the age of the child.</li><li>Rewards may also be given for drinking recommended levels of fluid during the day and for using the toilet before going to bed.</li><li>Reward systems that penalise the child or remove previously gained rewards are not recommended.</li><li>The child should not be punished for bedwetting as this has the potential to humiliatethe child and reducetheir self esteem.</li></ul></li></ul></li><li><strong>Provide additional sources of<a class="topic-reference internal-reference" href="index.html#sources-of-information-support">information and support</a>.</strong></li></ul><!-- end field 280ece48-708a-421c-b3b4-e705d174a34b --><!-- end item ef1efed1-57c7-47de-b1de-da92c60c55c9 --></div><section aria-labelledby="basis-for-recommendation-6ac" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-6ac">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6ac5ef5b-87fd-459d-b52d-73bf190ef728 --><!-- begin field 65e2cb7a-e95e-43c8-bcf9-8c6cb1faf083 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline<em>Nocturnal enuresis: the management of bedwetting in children and young people </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>]. The <a data-hyperlink-id="9ba1172e-d33d-4848-9766-ab8500cf164b" href="https://www.nice.org.uk/guidance/cg111/resources/2018-surveillance-of-bedwetting-in-under-19s-nice-guideline-cg111-6599305837/chapter/Overview-of-2018-surveillance-methods?tab=evidence">2018 NICEsurveillancereview</a> did not findsufficientnew evidence to warrant anupdate of the guideline.</p><h5>Reassurance</h5><ul><li>Treatment is generally not considered for children younger than 5years of age, as bedwetting is considered to be normal in this age group.</li><li>The European Association of Urology (EAU) states thatchildren younger than 5 years of age in whom spontaneous cure is likely should not be treated. However, the family/carers should be informedabout the involuntary nature of bedwetting, the high incidence of spontaneous resolution, and the fact that punishment will not help to improve the condition [<a class="bibliography-reference internal-reference" href="../../references/index.html">EAU, 2019</a>].</li></ul><h5>Fluid intake</h5><ul><li>The recommendation that children should have an adequate fluid intake is based on expert consensus opinion of the NICE guideline development group (GDG). NICE found no evidence that fluid restriction is effective for treating bedwetting and states that it is important to discuss adequate fluid intake with the parents or carers because:<ul><li>If fluids are restricted, the presence or absence of daytime symptoms may not be apparent.</li><li>If the child drinks adequate fluids during the day, this may prevent them from needing to drink larger quantities nearer bedtime.</li></ul></li><li>The NICE GDG noted that there is no evidence on the effect of fizzy drinks but were concerned that many children might be drinking caffeine-containing drinks (which are diuretics and bladder irritants) and that these might not be helpful in general or specifically for urinary symptoms. The GDG felt this was a good opportunity to reiterate these messages.</li></ul><h5>Diet</h5><ul><li>NICE found no evidence that restricting the child's diet is effective for treating bedwetting and recommends that it is important to make sure the child is eating healthily.</li></ul><h5>Toileting patterns</h5><ul><li>The recommendation that passing urine 47 times in a day is normal is based on the expert opinion of the NICE GDG.</li><li>The GDG extrapolated this frequency from the International Children's Continence Society (ICCS) criteria, which suggestthat less than 3 times per day or more than 8 times a day is abnormal.</li></ul><h5>Lifting</h5><ul><li>NICE found no evidence on lifting and advises that lifting does not promote long-term dryness.</li></ul><h5>Waking</h5><ul><li>NICE found very low-quality evidence that waking is effective for treating bedwetting.</li><li>The recommendation to use waking as a short-term, practical measure is based on the expert opinion of the NICE GDG.</li><li>The recommendation that self-instigated waking may be used in young people is also based on the expert opinion of the NICE GDG. They state that some young people successfully use waking to ensure dry nights, and should not be dissuaded from this.</li><li>The NICE GDG recommends that lifting without waking is potentially counterproductiveas the child does not learn to recognize the sensation of a full bladder.</li></ul><h5>Trial without pull ups or nappies</h5><ul><li>The recommendation to use a trial without pull ups or nappies is based on the expert opinion of the NICE GDG. The GDG felt that children (including those with behavioural or attention difficulties) in pull ups or nappies may be considered for a trialwithoutthem if they are toilet trained by day.</li></ul><h5>Reward systems</h5><ul><li>NICE identified 10randomized controlled trials that assessed the effectiveness of rewards systems; however, most of these studies were of low- or very-low-quality. Of these studies:<ul><li>One trial found that star charts were more effective than unstructured play therapy. This trial suggested that it is not just the interaction with the child that causes dryness, but the focus on bedwetting behaviours that leads to success.</li><li>Three trials found that dry bed training with an enuresis alarm, cognitive behaviour therapy, enuresis alarm, and stop-start training gave fewer wet nights; however, there was no difference for 14dry nights and drop-out rates.</li></ul></li><li>The NICE GDG states that reward systems are easier to implement than other treatments (such as dry bed training with an enuresis alarm, cognitive behavioural therapy, enuresis alarm, and stop-start training).</li><li>The recommendation to use reward systems alone in children who are able to achieve some dry nights is based on the expert opinion of the NICE GDG.</li></ul><h5>Sources of support</h5><ul><li>This recommendation is based on the expert opinion of the NICE GDG.</li></ul><h5>Treatments not recommended</h5><ul><li>Bladder training and retention control training are not recommended because:<ul><li>Only very poor-quality trials were identified for bladder training and retention control training, and the NICE GDGdid not believe that the evidence for the interventions was sufficient to recommend their use ahead of other treatments.</li><li>Although there was no evidence of harms from these studies, the NICE GDG felt that interrupting voiding or encouraging infrequent urination may promote voiding dysfunction.</li></ul></li><li>Dry bed training is not recommended because there is very poor-quality evidence to support its use. In addition, the GDG felt that some components of dry bed training were unacceptably punitive, inappropriate, and potentially psychologically damaging.</li></ul><!-- end field 65e2cb7a-e95e-43c8-bcf9-8c6cb1faf083 --><!-- end item 6ac5ef5b-87fd-459d-b52d-73bf190ef728 --></div></section></section><section aria-labelledby="management-children-5-years-older" class="ChapterBody-module--wrapper--2HCfk "><h3 id="management-children-5-years-older">How should I managebedwetting without daytime symptoms in children aged 5 years and older?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 52770809-79ff-4d41-b179-43ef288eb1c3 --><!-- begin field 399100de-8adf-4fe9-a8ff-0890ddabdb59 --><ul><li><strong>Explain that bedwetting is not the child or young person's fault.</strong><ul><li>It occurs because the volume of urine produced at night exceeds the capacity of the bladder to hold it, and the sensation of a full bladder does not wake the child or young person.</li></ul></li><li><strong>Reassure the parents or carers that </strong>bedwetting resolves as children get older because they develop an increased bladder capacity,<em>and/or</em>produce less urine at night,<em>and/or</em>learn to wake to the sensation of a full bladder.</li><li><strong>Give advice on:</strong><ul><li><strong>Diet andfluid intake.</strong>Advise that the child or young person should:<ul><li>Eat ahealthy diet; they shouldnot restrict their diet as a form of treatment for bedwetting.</li><li>Haveadequatedaily fluid intake. Recommended adequate daily fluid intake from drinks are:<ul><li>At 58years of age10001400mL (girls); 10001400mL (boys).</li><li>At 913years of age 12002100mL (girls); 14002300mL (boys).</li><li>At 1418years of age14002500mL (girls); 21003200mL (boys).</li></ul></li><li>Avoid drinking caffeine-based drinks (such as colas, coffee, and tea) before sleep.</li></ul></li><li><strong>Toileting patterns.</strong>Advise that:<ul><li>The child or young person shouldbe encouraged to empty their bladder regularly during the day and before sleep (between 47 times in total).</li><li>A waterproof mattress and duvet cover, absorbent quilted sheets, and bed pads can be used.</li><li>There should be easy access to a toilet at night.</li><li>If the child or young personhas been toilet trained by day for longer than 6months, they should consider a trial of at least 2nights in a row without nappies or pull ups (appropriate waterproof mattress protection will be required). A longer trial can be consideredin older children, children who achieve a reduction in wetness, and thosewhose family circumstances allow the trial to continue.</li></ul></li><li><strong>Lifting and waking.</strong>Advise that:<ul><li>Lifting or waking the child or young person during the night (at regular times or randomly) does not promote long-term dryness. However, if theywakeat night, they should be taken to the toilet.</li><li>Waking of children and young people should be used only as a practical measure in the short-term management of bedwetting.</li><li>Young people with bedwetting who have not responded to treatment may find self-instigated waking (for exampleusing a mobile phone alarm or alarm clock) a useful management strategy.</li></ul></li><li><strong>Positive reward systems.</strong>Advise that:<ul><li>Positive reward systems may be offered to children who have some dry nights.They should be adapted to the age of the child or young person.</li><li>Rewards may be given for drinking recommended levels of fluid during the day, using the toilet before going to bed, engaging in management (for example taking medication or helping to change sheets).</li><li>Reward systems that penalise the child or young person,or remove previously gained rewards are not recommended.</li><li>The child or young personshould not be punishedas this has the potential to humiliatethem and reducetheir self esteem.</li></ul></li></ul></li><li><strong>Offer treatmentto children and young people whose bedwetting has not responded to advice on fluids, toileting, or an appropriate reward system.</strong><ul><li>If rapid or short-term control of bedwetting is required(for example for sleepovers or school trips), offer treatment with <a class="topic-reference internal-reference" href="index.html#desmopressin">desmopressin</a>.</li><li>If long-term treatment is required,offer treatment with an<a class="topic-reference internal-reference" href="index.html#enuresis-alarms">enuresis alarm</a>(first-line treatment).<ul><li>A positive, age-appropriate reward systemshould be used with enuresis alarms to reward desired behaviour.</li><li>Desmopressinis less preferred but may be considered if an alarm is considered undesirable or innapropriate.</li></ul></li><li>If bedwetting is infrequent(less than twice a week), reassure the parents or carers that bedwetting may resolve without treatment and offer the option of a wait-and-see approach.</li></ul></li><li><strong>Provide additional sources of <a class="topic-reference internal-reference" href="index.html#sources-of-information-support">information and support</a>.</strong></li><li><strong>If bedwetting has not responded to at least two complete courses of treatment with either an alarm or desmopressin</strong> (this may be one course of each treatment, or two of the same),refer the child or young person to secondary care, an enuresis clinic, or a community paediatrician, depending on local protocols and availability.<ul><li>Further assessment is required for factors that may be associated with a poor response, such as an overactive bladder, an underlying disease, or social and emotional factors.</li><li>Tricyclic antidepressants (such as imipramine) or antimuscarinics (such as oxybutynin)may be initiated in secondary or primary care following an assessment by a healthcare professional with expertise in managing bedwetting.</li></ul></li></ul><!-- end field 399100de-8adf-4fe9-a8ff-0890ddabdb59 --><!-- end item 52770809-79ff-4d41-b179-43ef288eb1c3 --></div><section aria-labelledby="basis-for-recommendation-ded" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ded">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ded92e5c-9bf1-4bea-a56c-004b8fdd281f --><!-- begin field 33fa674d-de4e-4bf1-9dc4-5c139d58a9d6 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline<em>Nocturnal enuresis: the management of bedwetting in children and young people </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>]. The <a data-hyperlink-id="9ba1172e-d33d-4848-9766-ab8500cf164b" href="https://www.nice.org.uk/guidance/cg111/resources/2018-surveillance-of-bedwetting-in-under-19s-nice-guideline-cg111-6599305837/chapter/Overview-of-2018-surveillance-methods?tab=evidence">2018 NICEsurveillancereview</a> did not findsufficientnew evidence to warrant anupdate of the guideline.</p><h5>Fluid intake</h5><ul><li>The recommendation that children should have an adequate fluid intake is based on expert consensus opinion of the NICE guideline development group (GDG). NICE found no evidence that fluid restriction is effective for treating bedwetting and states that it is important to discuss adequate fluid intake with the parents or carers because:<ul><li>If fluids are restricted, the presence or absence of daytime symptoms may not be apparent.</li><li>If the child drinks adequate fluids during the day, this may prevent them from needing to drink larger quantities nearer bedtime.</li></ul></li><li>The recommendations regarding how much fluid to drink each day is based on the expert opinion of the NICE GDG.</li><li>The NICE GDG noted that there is no evidence on the effect of fizzy drinks but were concerned that many children might be drinking caffeine-containing drinks (which are diuretics and bladder irritants) and that these might not be helpful in general or specifically for urinary symptoms. The GDG felt this was a good opportunity to reiterate these messages.</li></ul><h5>Diet</h5><ul><li>NICE found no evidence that restricting the child's diet is effective for treating bedwetting and recommends that it is important to make sure the child is eating healthily.</li></ul><h5>Toileting patterns</h5><ul><li>The recommendation that passing urine 47 times in a day is normal is based on the expert opinion of the NICE GDG.</li><li>The GDG extrapolated this frequency from the International Children's Continence Society (ICCS) criteria, which suggestthat less than 3 times per day or more than 8 times a day is abnormal.</li></ul><h5>Lifting</h5><ul><li>NICE found no evidence on lifting and advises that lifting does not promote long-term dryness.</li></ul><h5>Waking</h5><ul><li>NICE found very low-quality evidence that waking is effective for treating bedwetting.</li><li>The recommendation to use waking as a short-term, practical measure is based on the expert opinion of the NICE GDG.</li><li>The recommendation that self-instigated waking may be used in young people is also based on the expert opinion of the NICE GDG. They state that some young people successfully use waking to ensure dry nights, and should not be dissuaded from this.</li><li>The NICE GDG recommends that lifting without waking is potentially counterproductiveas the child does not learn to recognize the sensation of a full bladder.</li></ul><h5>Trial without pull ups or nappies</h5><ul><li>The recommendation to use a trial without pull ups or nappies is based on the expert opinion of the NICE GDG. The GDG felt that children (including those with behavioural or attention difficulties) in pull ups or nappies may be considered for a trialwithoutthem if they are toilet trained by day.</li></ul><h5>Reward systems</h5><ul><li>NICE identified 10randomized controlled trials that assessed the effectiveness of rewards systems; however, most of these studies were of low- or very-low-quality. Of these studies:<ul><li>One trial found that star charts were more effective than unstructured play therapy. This trial suggested that it is not just the interaction with the child that causes dryness, but the focus on bedwetting behaviours that leads to success.</li><li>Three trials found that dry bed training with an enuresis alarm, cognitive behaviour therapy, enuresis alarm, and stop-start training gave fewer wet nights; however, there was no difference for 14dry nights and drop-out rates.</li></ul></li><li>The NICE GDG states that reward systems are easier to implement than other treatments (such as dry bed training with an enuresis alarm, cognitive behavioural therapy, enuresis alarm, and stop-start training).</li><li>The recommendation to use reward systems alone in children who are able to achieve some dry nights is based on the expert opinion of the NICE GDG.</li></ul><h5>Treatments</h5><ul><li>Enuresis alarm and desmopressin.<ul><li>See the sections on<a class="topic-reference internal-reference" href="index.html#enuresis-alarms">Enuresis alarms</a> and<a class="topic-reference internal-reference" href="index.html#desmopressin">Desmopressin</a> for more information.</li></ul></li><li>Wait-and-see approach.<ul><li>CKS recommends considering a wait-and-see approach for older children with infrequent bedwettingas this is more likely to resolve without treatment than frequent bedwetting.</li></ul></li></ul><h5>Sources of support</h5><ul><li>This recommendation is based on the expert opinion of the NICE GDG.</li></ul><h5>Referral</h5><ul><li>NICE recommends that children with primary bedwetting without daytime symptoms should be referred if symptoms have not responded to courses of treatment with an alarm and/or desmopressin. This is because these children may require further assessment of factors that may be associated with a poor response, such as an overactive bladder, an underlying disease, or social and emotional factors. However, they do not state how many courses may be tried before referral is considered.</li><li>Previous expert reviewers of this CKS topic felt that no more than two courses of treatment should be tried before referral because repeated failed attempts reduce the future success of treatment.</li><li>The NICE GDG stated that a tricyclic antidepressant (TCA) or an antimuscarinic may be considered if the child has not responded to all other treatment and has been assessed by a healthcare professional with expertise in the management of bedwetting. The GDG were specifically concerned about the potential adverse effects of TCAs and their danger in overdose.</li></ul><h5>Treatments not recommended</h5><ul><li>Bladder training and retention control training are not recommended because:<ul><li>Only very poor-quality trials were identified for bladder training and retention control training, and the NICE GDGdid not believe that the evidence for the interventions was sufficient to recommend their use ahead of other treatments.</li><li>Although there was no evidence of harms from these studies, the NICE GDG felt that interrupting voiding or encouraging infrequent urination may promote voiding dysfunction.</li></ul></li><li>Dry bed training is not recommended because there is very poor-quality evidence to support its use. In addition, the GDG felt that some components of dry bed trainingwere unacceptably punitive, inappropriate, and potentially psychologically damaging. The punitive elements were identified asrepetitive (20 times) positive practice, being told they were wet and informing visitors to the house they were trying to become dry, sleep loss even when dry (being woken to check if they were dry), and reprimanding.</li></ul><!-- end field 33fa674d-de4e-4bf1-9dc4-5c139d58a9d6 --><!-- end item ded92e5c-9bf1-4bea-a56c-004b8fdd281f --></div></section></section><section aria-labelledby="enuresis-alarms" class="ChapterBody-module--wrapper--2HCfk "><h3 id="enuresis-alarms">Enuresis alarms</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5fa580e8-5c08-4439-b82e-f9e4d8a9d661 --><!-- begin field 59c7c1b8-923f-45dc-abdf-407a789dce8b --><ul><li><strong>Enuresis alarms are generally considered as a first-line treatment for bedwetting unless:</strong><ul><li>The child or young person or their parents/carers do not want to use one.</li><li>The child or young person wets the bed (infrequently) less than once or twice a week.</li><li>Parents/carers have emotional difficulty coping with the burden of bedwetting.</li><li>Parents/carers express anger, negativity, or blame towards the child.</li><li>The child or young person is younger than 7years of age and is not able to use an alarm.<ul><li>The decision to use an alarm in a child younger than 7years of age is based on the child's maturity, their understanding of the alarm, and their motivation.</li></ul></li></ul></li><li><strong>Provide detailed information on enuresis alarms to the child or young person</strong><strong> and their parents/carers. </strong><ul><li>This should include information on the aims of alarm treatment, how the enuresis alarm works, and how to obtain an enuresis alarm (enuresis alarms cannot be prescribed on the NHS).</li><li>Advise that enuresis alarms have a high long-term success rate,but they may not suit all families. Using an alarm involves a significant commitment from the child or young person and the parents/carers.</li><li>Advise that apositive, age-appropriate reward systemshould be used with enuresis alarms to reward desired behaviour.</li><li>See the section on <a class="topic-reference internal-reference" href="index.html#information-advice">Information on enuresis alarms</a> for further information.</li></ul></li><li><strong>Assess response after 4weeks:</strong><ul><li>If there are no signs of a response (such assmaller wet patches, fewer wetting episodes per night, fewer wet nights),stop the treatment.</li><li>If there are signs of a response, continue alarm treatment until a minimum of 2 weeks' uninterrupted dry nights has been achieved.</li><li>If complete dryness is not achieved after 3 months, assess whether it is appropriate to continue with alarm treatment. Only continue with alarm treatment if the bedwetting is still improving and the child or young person and parents/carers are motivated to continue.</li></ul></li><li><strong>If bedwetting does not respond to initial alarm treatment,</strong>consider offering:<ul><li>Combination treatment with an alarm and<a class="topic-reference internal-reference" href="index.html#desmopressin">desmopressin</a>,<em>or</em></li><li>Desmopressin alone if the child or young person and/or the parents/carers do not want to continue using an enuresis alarm.</li></ul></li><li><strong>If there is a partial response to combination treatment</strong><strong>of an alarm and desmopressin,</strong> consider offering desmopressin alone.</li></ul><!-- end field 59c7c1b8-923f-45dc-abdf-407a789dce8b --><!-- end item 5fa580e8-5c08-4439-b82e-f9e4d8a9d661 --></div><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h4 id="information-advice">What information and advice shouldI give parents or carers regarding enuresis alarms?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 040bab50-8346-4b4c-b407-13819eafee65 --><!-- begin field ec251c8f-ce34-4084-91a8-6881014aa5f6 --><ul><li><strong>Explain that enuresis alarms have sensor pads that sense wetness.</strong><ul><li>The sensor is linked to an alarm that wakes the child or young person if it becomes wet.</li><li>There are two main types of enuresis alarms:<ul><li>Beside alarms  where a noise box is placed next to the child or young person's bed and a sensor pad is positioned under a draw sheet beneath the child or young person in the bed.</li><li>Body-worn alarms<strong></strong>where a tiny sensor is attached to the child or young person's pants, for example between two pairs of tightly fitting underpants, and the alarm is worn on the pyjama top.</li></ul></li><li>Vibrating alarmsare also available for those with a hearing impairment.</li></ul></li><li><strong>Explain that the aims of alarm treatment are to train the child or young person to:</strong><ul><li>Recognize the need to pass urine.</li><li>Wake to go to the toilet or hold on.</li><li>Learn over time to hold on or to wake spontaneously, and stop wetting the bed.</li></ul></li><li><strong>Advise that:</strong><ul><li>Alarms have a high long-term success rate,but they may not suit all families. Using an alarm involves a significant commitment from the child or young person and the parents/carers:<ul><li>The child or young person and the parents/carers will require training on how to use the alarm.</li><li>The alarm can disrupt sleep.</li><li>The parents/carers may need to help the child or young personto wake to the alarm.</li><li>A record of the child or young person's progress should be kept (for example if and when they wakeand how wet they are).</li><li>Alarms are most effective when used by experienced practitioners (with frequent follow up every 34weeks).</li></ul></li><li>A positive, age-appropriate reward systemshould be used with enuresis alarms to reward desired behaviour.Behaviour that should be rewarded includes:<ul><li>Waking up when the alarm goes off.</li><li>Going to the toilet after the alarm has gone off.</li><li>Returning to bed and resetting the alarm.</li></ul></li><li>It may take a few weeks for the early signs of a response to the alarm to occur.Signs of a response include:<ul><li>Smaller wet patches.</li><li>Waking to the alarm.</li><li>The alarm going off later and fewer times per night.</li><li>Fewer wet nights.</li></ul></li><li>Dry nights may take weeks to achieve and may be a late sign of response to the alarm.</li><li>If the child or young person relapses following response to alarm treatment, they should start using the alarm again. There is no need to consult a healthcare professional.</li></ul></li><li><strong>Enuresis alarms cannot be prescribed on the NHS.</strong><ul><li>They can be borrowed from the local enuresis adviser orboughtprivately from ERIC (The Children's Bowel & Bladder Charity, telephone 08453708008,<a href="http://www.eric.org.uk/" data-hyperlink-id="0457f2b6-2ea0-4c87-bfd5-a98f003eb6a6">www.eric.org.uk</a>).</li></ul></li></ul><!-- end field ec251c8f-ce34-4084-91a8-6881014aa5f6 --><!-- end item 040bab50-8346-4b4c-b407-13819eafee65 --></div></section><section aria-labelledby="basis-for-recommendation-117" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-117">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 117b9503-c32b-455e-a8e5-c3af91f6f5d9 --><!-- begin field fc59e02b-391f-4826-8f90-dd9473d7c92e --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline<em>Nocturnal enuresis: the management of bedwetting in children and young people </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>]. The <a data-hyperlink-id="9ba1172e-d33d-4848-9766-ab8500cf164b" href="https://www.nice.org.uk/guidance/cg111/resources/2018-surveillance-of-bedwetting-in-under-19s-nice-guideline-cg111-6599305837/chapter/Overview-of-2018-surveillance-methods?tab=evidence">2018 NICEsurveillancereview</a> did not findsufficientnew evidence to warrant anupdate of the guideline.</p><h5>Enuresis alarms</h5><ul><li>The NICE guideline development group (GDG) found low-quality evidence from randomized controlled trials (RCTs) that when compared with no treatment, enuresis alarms were effective for treating bedwetting (effectiveness was defined as 14consecutive dry nights, or a mean reduction in the number of wet nights at the end of treatment).<ul><li>NICE recommends treatment with an enuresis alarm as a first-line option becausealthough they found that there was no significant difference between desmopressin and enuresis alarms, they also found that bedwetting was more likely to recur in children treated with desmopressin when desmopressin treatment was stopped. Enuresis alarms are thought to develop a conditioned response of waking in response to a full bladder, which is more likely to continue after stopping alarm treatment.</li><li>Enuresis alarms may not be suitable for all families because they require considerable effort and perseverance from the child and family.<ul><li>The NICE GDG considered that it was important that families were motivated to use an alarmand that in families already struggling to cope with bedwetting, the introduction of an alarm may result in punishment of the child.</li><li>Infrequent bedwetting is more likely to resolve spontaneously than frequent bedwetting.</li></ul></li></ul></li><li>A subsequentnetwork meta-analysis assessed theefficacy of enuresis alarms, desmopressin, desmopressin plus alarm, and desmopressin plus anticholinergic agent treatment in themanagement ofpaediatric nocturnalenuresis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Song, 2019</a>].<ul><li>Desmopressin had similarefficacy to alarm therapy but a higher relapserate.</li><li>Desmopressin plus alarm therapy wassimilar toboth desmopressin and alarm monotherapy inefficacy.</li><li>All treatments wereassociated with tolerableadverseevents.</li></ul></li></ul><h5>Children younger than 7 years of age</h5><ul><li>The recommendation that enuresis alarms may be considered in children 57years of age is based on the expert opinion of the NICE GDG. The GDG felt that although children in this age group may not require treatment, they should not be denied treatment with an enuresis alarm if they are mature enough and motivated enough to cope with using one.</li><li>Treatment is generally not considered for children younger than 5years of age as bedwetting is considered to be normal in this age group.</li></ul><h5>Information on enuresis alarms</h5><ul><li>The NICE GDG considered that it was important to give parents/carers as much information and advice as possible if they are considering using an enuresis alarm. Enuresis alarms can be difficult for a child and parent/carers to use, and families may need considerable advice and support. Information that the NICE GDG considered essential were:<ul><li>How to use the alarm.</li><li>What to expect from treatment.</li><li>The signs of response to look out for.</li><li>Information about dealing with problems with the alarm and how to return it.</li><li>Offering and agreeing appropriate support.</li></ul></li><li>The recommendation to use a reward system in combination with an enuresis alarm is based on evidence from one very low-quality RCT and on the expert opinion of the NICE GDG.</li></ul><!-- end field fc59e02b-391f-4826-8f90-dd9473d7c92e --><!-- end item 117b9503-c32b-455e-a8e5-c3af91f6f5d9 --></div></section></section><section aria-labelledby="desmopressin" class="ChapterBody-module--wrapper--2HCfk "><h3 id="desmopressin">Desmopressin</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 01dfa640-e08c-4dba-b021-f8649b62ae3e --><!-- begin field 0049d529-5973-43db-b5b2-f66f4afcd94f --><ul><li><strong>Consider prescribing desmopressin if:</strong><ul><li>A rapid onset in improvement or a short-term improvement is required (for example for sleepovers or school trips).<ul><li>Consider starting a trial of desmopressin at least 1week before the school trip or sleepoverto determine the effectiveness of treatment.</li></ul></li><li>The child or young person and their parents/carers are currently using an<a class="topic-reference internal-reference" href="index.html#enuresis-alarms">enuresis alarm</a>and want to stop.</li><li>The child or young person and their parents/carers are unable or unwilling to use an enuresis alarm as first-line treatment.<ul><li>This includes children 57years of age, who may not be considered mature enough to use an enuresis alarm.</li></ul></li></ul></li><li><strong>Give<a class="topic-reference internal-reference" href="index.html#information-advice">advice</a>on how desmopressin works,</strong> and explain that there is usually a rapid response to treatment.</li><li><strong>Prescribe a low dose of oral desmopressin(Desmotabs<sup></sup>200micrograms or sublingual DesmoMelt<sup></sup>120micrograms) initially, at bedtime.</strong><ul><li>If there is a responseto desmopressin, continue the treatment.</li><li>If complete dryness has not been achieved after 12weeks of treatment with low-dose desmopressin, consider advising the parents to increase the dose of desmopressin (to Desmotabs<sup></sup>400micrograms or DesmoMelt<sup></sup>240micrograms).</li></ul></li><li><strong>Assess the response 4weeks after starting treatment.</strong><ul><li>If there are signs of a response(smaller wet patches, fewer wetting episodes per night, fewer wet nights), continue treatment for 3months.<ul><li>Stop desmopressin after 3months for 1week to check whether dryness has been achieved (repeated courses may be used).</li></ul></li><li>If there is a partial response to desmopressin, consider:<ul><li>Advising the parents/carersto increase the dose of desmopressin (to Desmotabs<sup></sup>400micrograms or DesmoMelt<sup></sup>240micrograms).</li><li>Advising the child to take desmopressin 12hours before bedtime.</li><li>Continuing treatment for another 6monthsbedwetting may improve for up to 6months after starting treatment.</li></ul></li><li>If there are no signs of a response, consider:<ul><li>Stopping treatment with desmopressin,<em>or</em></li><li>Continuing desmopressin treatment and recommending that it is taken 12hours before bedtime (ensure the child can comply with a fluid restriction for 1hour before desmopressin is taken).</li></ul></li></ul></li><li><strong>Review the child or young person regularly if desmopressin is being used long term.</strong><ul><li>Do notroutinely measure weight, serum electrolytes, blood pressure, and urine osmolality.</li></ul></li><li><strong>Seek specialist advice if desmopressin is being considered for children or young people with:</strong><ul><li>Sickle cell diseasethe concentrating ability of the kidneys may be lost in children with sickle cell disease, resulting in high urine output.</li><li>Cystic fibrosis  case reports recommend caution because of altered handling of electrolytes.</li><li>Behavioural, attentional, and emotional disorders  the child may not be able to comply with fluid restrictions.</li></ul></li></ul><!-- end field 0049d529-5973-43db-b5b2-f66f4afcd94f --><!-- end item 01dfa640-e08c-4dba-b021-f8649b62ae3e --></div><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h4 id="information-advice">What information and advice should I give parents or carers regarding desmopressin?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 08fc6249-93f9-442f-96d2-c801f6d7f5b8 --><!-- begin field f7afaf1e-2eea-42b2-8e59-ecea72d4f075 --><ul><li><strong>Advise that:</strong><ul><li>Desmopressin should be taken at bedtime.<ul><li>It works by reducing the amount of urine the body produces at night; this mimics the action of the body's own naturally occurring antidiuretic hormone (ADH).</li><li>In most children and young people, levels of ADH rise overnight and reduce the volume of water excreted by the kidneys compared with during the daytime.</li></ul></li><li>Many children andyoung people, but not all, will:<ul><li>Experience a reduction in wetness.</li><li>Relapse when treatment is withdrawn. If the child or young personrelapses, repeated courses may be used.</li></ul></li><li>Fluid intake should be restricted to sips only, from 1hour before taking desmopressin until 8hours afterwards (a total of one regular glass of water may be drunk in this time). Fluid restriction is required to avoid the potential for fluid overload and hyponatraemia (low sodium levels in the blood), which can lead to hyponatraemic convulsions. Also advise that:<ul><li>The child or young personshould avoid swallowing water when swimming (to avoid fluid overload).</li><li>Over the counter nonsteroidal anti-inflammatories, such as ibuprofen, should be avoided as they can cause water retention and increase the risk of hyponatraemia.</li><li>Desmopressin should be stopped if the child or young personhas vomiting or diarrhoea, until fluid balance is normal.</li></ul></li></ul></li></ul><!-- end field f7afaf1e-2eea-42b2-8e59-ecea72d4f075 --><!-- end item 08fc6249-93f9-442f-96d2-c801f6d7f5b8 --></div></section><section aria-labelledby="basis-for-recommendation-d97" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-d97">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d974a480-d075-47aa-bcf4-ab8500bba694 --><!-- begin field 365a6f43-3ecc-493d-8255-ab8500bba6df --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline<em>Nocturnal enuresis: the management of bedwetting in children and young people </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>]. The <a data-hyperlink-id="9ba1172e-d33d-4848-9766-ab8500cf164b" href="https://www.nice.org.uk/guidance/cg111/resources/2018-surveillance-of-bedwetting-in-under-19s-nice-guideline-cg111-6599305837/chapter/Overview-of-2018-surveillance-methods?tab=evidence">2018 NICEsurveillancereview</a> did not findsufficientnew evidence to warrant anupdate of the guideline.</p><h5>Desmopressin</h5><ul><li>The NICE guideline development group (GDG) found very low-quality to moderate-quality evidence from randomized controlled trials (RCTs)that desmopressin was effective for treating bedwetting (effectiveness was defined as 14consecutive dry nights or a mean reduction in the number of wet nights at the end of treatment).<ul><li>Oral desmopressin is a recommended first-line for children who require a rapid response or short-term control of bedwetting (for example for sleepovers or school trips) because it has a faster response rate than enuresis alarms. It may take a few weeks for the child to respond to an enuresis alarm, whereas children treated with desmopressin usually respond rapidly.</li><li>Nasal desmopressin is no longer licensed for treating primary bedwetting because a significantly higher incidence of symptomatic hyponatraemia has been reported compared with oral desmopressin[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2007</a>].</li></ul></li><li>A subsequentnetwork meta-analysis assessed theefficacy of desmopressin, enuresis alarms, desmopressin plus alarm, and desmopressin plus anticholinergic agent treatment in themanagement ofpaediatric nocturnalenuresis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Song, 2019</a>].<ul><li>Desmopressin had similarefficacy to alarm therapy but a higher relapserate.</li><li>Desmopressin plus alarm therapy wassimilar toboth desmopressin and alarm monotherapy inefficacy.</li><li>Desmopressin plus anticholinergic treatment was associated with betterefficacy than and a similar relapserateto desmopressin monotherapy.</li><li>All treatments wereassociated with tolerableadverseevents.</li></ul></li></ul><h5>Use of desmopressin in children younger than 7 years of age</h5><ul><li>The recommendation to consider treatment with desmopressin in children 57years of age is based on evidence from one very low-quality RCT. This trial found that children 6.6years of age (mean age) who received a short course of desmopressin had a reduced number of wet nights during treatment. There was no difference with regards to achieving 14consecutive dry nights. The NICE GDG concluded that desmopressin could be used in children aged between 57years, particularly if short-term treatment is necessary.</li><li>Treatment for bedwetting is generally not considered for children younger than 5years of age, as bedwetting is considered to be normal in younger children and usually resolves without treatment. In addition,desmopressin is not licensed for use in children younger than 5years of age.</li></ul><h5>Dose and timing of desmopressin</h5><ul><li>The information on the dose of desmopressin is based on the NICE guideline[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>].</li><li>The recommendation to start desmopressin at lower doses and increase to a maximum dose is based on expert opinion from the NICE GDG, because some children will achieve benefit on lower doses.</li><li>The recommendations to take desmopressin 12hours earlier if there has been no response or a partial response is based on the experience of the GDG and on the pharmacokinetics of desmopressin</li></ul><h5>Monitoring</h5><ul><li>The NICE GDG considered that there was no evidence of need to monitor weight, serum electrolytes, blood pressure, and urine osmolality in children being treated with desmopressin. They considered that this idea of monitoring children on desmopressin may have arisen because of the other clinical conditions for which desmopressin may be used.</li></ul><!-- end field 365a6f43-3ecc-493d-8255-ab8500bba6df --><!-- end item d974a480-d075-47aa-bcf4-ab8500bba694 --></div></section></section><section aria-labelledby="managing-recurrence" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-recurrence">How should I manage children and young people who have been successfully treated and start to wet the bed again?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ec60d786-116d-4902-b872-d466fadd5039 --><!-- begin field 9e464560-a942-4b77-aaef-a6373b6fbb93 --><ul><li><strong>For children and young people who have been treated successfully with an <a class="topic-reference internal-reference" href="index.html#enuresis-alarms">enuresis alarm</a> and start wetting the bed again:</strong><ul><li>Restart alarm treatment,<em>or</em></li><li>If there is more than one recurrence of bedwetting, offer combination treatment with an alarm and <a class="topic-reference internal-reference" href="index.html#desmopressin">desmopressin</a>.</li></ul></li><li><strong>For children and young people whohave respondwell to desmopressin but experience recurrencewhen treatment is withdrawn, consider:</strong><ul><li>Prescribing another course of desmopressin (repeated courses may be used).<ul><li>Withdraw desmopressin treatment at regular intervals (for 1week every 3months) to check whether dryness has been achieved.</li></ul></li><li>Gradually withdrawing desmopressin rather than stopping it suddenly.<ul><li>A suitable withdrawal regimen used in clinical trials was an increase of 'no-medication days' over an 8-week period.</li></ul></li><li>Using an enuresis alarm instead of restarting desmopressin, if an alarm is now considered appropriate and the child or young person and/or their parents/carers want to try one.</li></ul></li></ul><!-- end field 9e464560-a942-4b77-aaef-a6373b6fbb93 --><!-- end item ec60d786-116d-4902-b872-d466fadd5039 --></div><section aria-labelledby="basis-for-recommendation-1ba" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1ba">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1ba2b754-3b1c-4011-9750-0326ef06a79b --><!-- begin field fcda5429-fafe-4b22-897b-f4c3817d5aa0 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline<em>Nocturnal enuresis: the management of bedwetting in children and young people </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Clinical Guideline Centre, 2010</a>].The <a href="https://www.nice.org.uk/guidance/cg111/resources/2018-surveillance-of-bedwetting-in-under-19s-nice-guideline-cg111-6599305837/chapter/Overview-of-2018-surveillance-methods?tab=evidence" data-hyperlink-id="9ba1172e-d33d-4848-9766-ab8500cf164b">2018 NICEsurveillancereview</a> did not findsufficientnew evidence to warrant anupdate of the guideline.</p><h5>Managing recurrences</h5><ul><li>These recommendations are based on expert opinion of the NICE guideline development group (GDG). The NICE GDG used their professional experience and health economic assessment to make these recommendations as no trial evidence was identified to guide recommendations.</li></ul><h5>Gradual withdrawal from desmopressin</h5><ul><li>NICE found evidence from two observational studies that showed that slow withdrawal of desmopressin might reduce relapse. These studies used the following withdrawal schedules:<ul><li>A gradual reduction of dosage by 10micrograms every 4weeks.</li><li>An increase in 'no-medication days' over an 8-week period.</li></ul></li><li>The NICE GDG felt that there was no strong evidence for either approach and the method of withdrawal should be up to the healthcare professional and the child or young person's family/carers.</li></ul><!-- end field fcda5429-fafe-4b22-897b-f4c3817d5aa0 --><!-- end item 1ba2b754-3b1c-4011-9750-0326ef06a79b --></div></section></section><section aria-labelledby="sources-of-information-support" class="ChapterBody-module--wrapper--2HCfk "><h3 id="sources-of-information-support">What are the available sources of information and support?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1fdff690-5811-463e-b0d5-ab85007aebc3 --><!-- begin field 115fd132-9ddf-482a-b178-ab85007aec9b --><ul><li><strong>Information and support on bedwetting is available from:</strong><ul><li>ERIC, The Children's Bowel and Bladder Charity(<a href="https://www.eric.org.uk/pages/category/bedwetting" data-hyperlink-id="a3993971-b487-40a4-9db0-ab8500faefe7">www.eric.org.uk</a>).<ul><li>The <a href="https://www.eric.org.uk/Handlers/Download.ashx?IDMF=2389eff8-420a-45f1-956c-14f2323361f5" data-hyperlink-id="d6dd41eb-af0d-4790-bc7a-ab8500faf049">ERIC's Guide to Night Time Wetting</a>isa leaflet aboutnight time wettingproblems for children and their parents/carers.</li><li>The ERIC online shop has a range of other<a href="https://www.eric.org.uk/pages/shop/department/informationleaflets?dept=informationleaflets" data-hyperlink-id="3d5809b4-7b13-4e7a-8b2b-ab8500faf05f">leaflets</a>, <a href="https://www.eric.org.uk/pages/shop/department/books?dept=books" data-hyperlink-id="f4d249be-afab-419f-93ef-ab8500faf0b7">books</a>, and continence products, including<a href="https://www.eric.org.uk/pages/shop/department/bedwetting-alarms?dept=bedwetting-alarms" data-hyperlink-id="49093f86-ee91-46a0-9ddc-ab8500faf11e">enuresis alarms</a>.</li></ul></li><li>TheBladder and Bowel Community (<a href="https://www.bladderandbowel.org/" data-hyperlink-id="1e57f1ee-3804-42bf-86ad-ab8500faf1cf">www.bladderandbowel.org</a>).</li><li>The NHS website (<a href="https://www.nhs.uk/conditions/bedwetting/" data-hyperlink-id="f58817ee-b60b-4ce2-9f86-ab8500faf22e">www.nhs.uk</a>).</li></ul></li></ul><!-- end field 115fd132-9ddf-482a-b178-ab85007aec9b --><!-- end item 1fdff690-5811-463e-b0d5-ab85007aebc3 --></div></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/bedwetting-enuresis/management/primary-bedwetting-without-daytime-symptoms/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>